Oncolytics Schedules Type C Meeting With FDA For Pelareorep In Anal Cancer

Oncolytics Biotech scheduled a Type C meeting with the FDA for April 16, 2026 to discuss a potential registrational development path for its lead investigational immunotherapy. The company is a clinical-stage immunotherapy firm; the meeting is a regulatory planning discussion and does not convey immediate approvals or material financial impacts, though it could shape a future pivotal/approval strategy.

Analysis

Oncolytics Biotech scheduled a Type C meeting with the FDA for April 16, 2026 to discuss a potential registrational development path for its lead investigational immunotherapy. The company is a clinical-stage immunotherapy firm; the meeting is a regulatory planning discussion and does not convey immediate approvals or material financial impacts, though it could shape a future pivotal/approval strategy.